{"preliminary_commentary":{"by_channel":{"x_thread":46,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03210103\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-18T02:58:39.122Z","note":"Automated from the 38 newest of 48 indexed sources (Mar 2019 – Oct 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":38,"text":"- How surgeon credentialing and surgical outcomes in the transoral surgery arm compare with E3311 and MC1675\n- Whether early closure leaves the trial too small and immature to compare oncologic outcomes between arms\n- Whether the radiotherapy arm's event rate is consistent with real-world outcomes outside the trial\n- Whether the trial should end routine transoral surgery as a de-escalation approach in HPV-positive disease","kind":"questions"},"drugs_tested":[],"indication":"HPV-associated oropharyngeal squamous cell carcinoma","name":"ORATOR2","nct_id":"NCT03210103","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=orator2-nct03210103. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ORATOR2","arms":[{"description":"Standard Treatment (Radiation +/- Chemotherapy)","label":"Arm 1, Radiation +/- Chemotherapy","type":"ACTIVE_COMPARATOR"},{"description":"Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)","label":"Arm 2, TOS + Neck Dissection","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-08-15","type":"ESTIMATED"},"conditions":["Oropharyngeal Cancer"],"enrollment":{"count":61,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Radiation","otherNames":["Chemotherapy, if required"],"type":"RADIATION"},{"name":"Transoral Surgery (TOS) + Neck Dissection","otherNames":["Radiation, if required"],"type":"PROCEDURE"}],"last_update":"2026-01-28","lead_sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","official_title":"A Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR II)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2028-08-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"2 years"}],"references":[{"citation":"Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Richardson K, Mlynarek A, Johnson-Obaseki S, Gaudet M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Kwan K, Theurer J, Bahig H, Christopoulos A, Mendez LC, Sathya J, Hammond JA, Read N, Venkatesan V, Fung K, Nichols AC. Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial. Eur J Cancer. 2025 May 2;220:115343. doi: 10.1016/j.ejca.2025.115343. Epub 2025 Mar 10.","pmid":"40121836","type":"DERIVED"},{"citation":"Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Sultanem K, Richardson K, Mlynarek A, Johnson-Obaseki S, Odell M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Krishnan S, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Wehrli B, Kwan K, Theurer J, Sathya J, Hammond JA, Read N, Venkatesan V, MacNeil SD, Fung K, Nichols AC. Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022 Jun 1;8(6):1-7. doi: 10.1001/jamaoncol.2022.0615.","pmid":"35482348","type":"DERIVED"},{"citation":"Nichols AC, Lang P, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Fung K, de Almeida JR, Bayley A, Goldstein DP, Eskander A, Husain Z, Bahig H, Christopoulous A, Hier M, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Mendez A, Winquist E, Read N, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Corsten M, Rajaraman M, Johnson-Obaseki S, Eapen L, Odell M, Chandarana S, Banerjee R, Dort J, Matthews TW, Hart R, Kerr P, Dowthwaite S, Gupta M, Zhang H, Wright J, Parker C, Wehrli B, Kwan K, Theurer J, Palma DA. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial. BMC Cancer. 2020 Feb 14;20(1):125. doi: 10.1186/s12885-020-6607-z.","pmid":"32059705","type":"DERIVED"}],"start_date":{"date":"2018-01-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer","url":"https://clinicaltrials.gov/study/NCT03210103"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/orator2-nct03210103"}